Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival
Mondul AM, Weinstein SJ, Moy KA, Männistö S, Albanes D
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 34 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
- Government
- National Institutes of Health
- Government
- U.S. Public Health Service
- Government
- National Cancer Institute
- Government
- NCI NIH HHS
- Government
- CCR NIH HHS
- Government
- Intramural NIH HHS
- Grants
- U.S. Public Health Service (HHSN261200800001E); U.S. Public Health Service (N01-RC-37004); U.S. Public Health Service (HHSN261201000006C); National Cancer Institute (HHSN261200800001E)); U.S. Public Health Service (N01-CN-45165); National Cancer Institute (HHSN261201000006C); National Cancer Institute (HHSN261201500005C); U.S. Public Health Service (HHSN261201500005C); National Institutes of Health (HHSN261200800001C); National Cancer Institute (N01 CN045165); U.S. Public Health Service (N01-RC- 45035); National Institutes of Health (N01 RC037004); National Institutes of Health (Z01 CP010195)
Based on 6 listed funder(s).
Publication
- Published
- 2016-01-25 · Cancer Epidemiol Biomarkers Prev · vol. 25 · issue 4 · pp. 665–669
- Publisher
- American Association for Cancer Research
- Cited
- 58 citations · more than 97% of similar papers · 6.0× the field average
- Impact
- Top 10% most cited in its field
- References
- 25 works
- Access
- Open access (repository copy)
- Research areas
- Vitamin D Research Studies · Bone health and treatments · Thyroid Disorders and Treatments
- Keywords
- Prostate cancer, Medicine, Hazard ratio, Cancer, Vitamin D and neurology, Internal medicine, Proportional hazards model, Prostate, Confidence interval, Oncology, Population, Cohort, Malignancy, Cohort study, Gynecology
- MeSH
- humans, prostatic neoplasms, vitamin d, survival analysis, double-blind method, aged, middle aged, male
5 authors
From US, FI
- Alison M. Mondul · correspondingUniversity of Michigan; Department of Health and Human Services
- Stephanie J. WeinsteinDepartment of Health and Human Services
- Kristin A. MoyDepartment of Health and Human Services
- Satu MännistöFinnish Institute for Health and Welfare
- Demetrius AlbanesDepartment of Health and Human Services
Abstract
Background
Recent epidemiologic evidence suggests that higher circulating vitamin D does not protect against prostate cancer and, in fact, may increase the risk of developing this malignancy. However, few studies have examined the most clinically relevant outcome, prostate cancer mortality.
Methods
We examined prediagnostic serum 25-hydroxy-vitamin D (25(OH)D) and prostate cancer survival in a cohort of 1,000 cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. During 23 years of follow-up, 363 men died from their disease. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of death from prostate cancer by season-specific quintile of 25(OH)D. Multivariable models were adjusted for age, physical activity, cigarettes per day, and family history of prostate cancer.
Results
Men with higher serum 25(OH)D were less likely to die from their prostate cancer (Q5 vs. Q1 HR, 0.72; 95% CI, 0.52-0.99; Ptrend = 0.006). This finding was independent of stage or grade at diagnosis and appeared restricted to men who survived longer (survived <3.3 years: Q5 vs. Q1 HR, 0.95; 95% CI, 0.61-1.50; Ptrend, 0.53; survived ≥3.3 years: Q5 vs. Q1 HR, 0.53; 95% CI, 0.34-0.85; Ptrend, 0.0002).
Conclusions
In this population of men diagnosed with prostate cancer, higher serum 25(OH)D years prior to diagnosis was associated with longer prostate cancer survival.
Impact
In light of inconsistent evidence regarding the role of vitamin D in the development of prostate cancer, the present findings regarding the most clinically relevant prostate cancer outcome, disease-specific mortality, could have important public health implications. Cancer Epidemiol Biomarkers Prev; 25(4); 665-9. ©2016 AACR.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.